Tevogen Bio Holdings Inc. (TVGN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
15 Independence Blvd
Warren, NJ 07059
United States of America (the)
Phone
877 838 6436
Website
Sector
Healthcare
Industry
Biotechnology
Employees
18
First IPO Date
January 05, 2022
| Name | Title | Pay | Year Born |
| Ryan H. Saadi | Co-Founder, Chief Executive Officer & Chairperson | 501,000 | 1965 |
| Kirti Desai | Chief Financial Officer | 300,000 | 1957 |
| Neal Flomenberg | Chief Scientific Officer and Global R&D Lead | 350,000 | 1954 |
| Mittul Mehta | Chief Information Officer & Head of Tevogen.ai | 0 | N/A |
| Tapan V. Shah | Head of Investor Relations & Corporate Development | 0 | N/A |
| Sadiq Khan | Chief Commercial Officer & Interim Head of Tevogen Generics | 0 | 1962 |
| David E. Banko | Global Head of Government Affairs & Patient Access | 0 | N/A |
| Stephen Chen | Chief Technical Officer | 0 | N/A |
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.